CME 1 Session - EANM'16

Paediatrics/Oncology/ELI: PET in Lymphoma: What are the New Fields in Adult and Paediatric Practice?

Educational objectives:
  1. To learn about the role of PET in the European treatment optimization protocol from 2007–2013 for paediatric Hodgkin’s lymphoma and the obtained treatment results
  2. To attain knowledge about the new European treatment optimization protocol which has been opened in 2016. What is new for the nuclear physician?
  3. To compare the role of visual and quantitative reading of interim PET scans and learn about different evaluation methods
  4. To learn about the different PTCL subtypes and the role of PET in staging
  5. To learn about the current prognostic indices and the prognostic value of baseline quantitative PET parameters
  6. To underline the possible role of PET in response assessment
  7. To learn about the role of tissue biomarkers in Hodgkin lymphoma and Diffuse large B cell
  8. To lean about the prognostic role of Metabolic Tumor Volume at staging
  9. To learn about the complementary role of Q-PET and tissue biomarker for risk stratification

As defined by the educational objectives

Key Words:

Paediatric Hodgkin lymphoma, interim PET, Deauville scale, Q-PET, EuroNet-PHL trials, Peripheral T cell Lymphoma, Total metabolic Tumor Volume, Interim PET, end of treatment PET lymphoma, CD68 macrophages, Hodgkin lymphoma, DLBCL, microenvironment.

User action required
If you have the permission to view this publication, please log in.